on ABIONYX (EPA:ABNX)
ABIONYX Pharma presents the results of the RACERS study
ABIONYX Pharma announced that the results of its RACERS study will be presented at the American Society of Nephrology Kidney Week in 2024. The phase 2b study focuses on the treatment of brain fog associated with sepsis, showing positive effects on cognitive impairment.
The data reveal that CER-001, a biologic, alleviates brain dysfunction by regulating the enzyme IDO1, which is linked to kynurenine metabolism, which is strongly involved during inflammation.
The results indicate an increase in tryptophan and kynurenic acid, suggesting neuroprotection. Professor Loreto Gesualdo pointed out that CER-001 could improve cognitive functions in septic patients.
These results support the potential of CER-001 in the treatment of neuroinflammation, opening the way to new indications.
R. H.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ABIONYX news